A thrombocytaaggregáció-gátló és az antikoaguláns kezelés aktuális szempontjai a stroke prevenciójában

Translated title of the contribution: Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke

Research output: Contribution to journalArticle

Abstract

About 80% of strokes have ischemic origin. Therapeutical options of acute stroke are still limited and the occurrence of recurrent strokes is remarkably high. Consequently, the adequate stroke prevention has a high importance. The two main components of prevention are the inhibition of platelet aggregation and the anticoagulant therapy. Results of multicenter drug trials showed that antiaggregation therapy can reduce the risk of recurrent stroke by ca. 25%. Acetylsalicylate has been used for stroke prevention for decades. Nowadays, there is a broad spectrum of available platelet aggregation inhibitors. The efficacy of these new drugs is higher than that of acetylsalicylate. According to recent therapeutical guidelines, the antiaggregation therapy of patients with non-cardiometabolic stroke should be optimized individually. The most frequent cause of cardiogenic stroke is atrial fibrillation. The importance of anticoagulation therapy has been proved by large multicenter studies. Absolute therapeutical indications are the elder age, additional risk factors, previous stroke. Therapeutical guidelines in other cardiological disorders associated with high risks for stroke need further drug trials. Fifty years after the introduction of warfarin, in the last years new direct thrombin inhibitors have been developed. These drugs have the same efficacy as warfarin but they are a more safety and have more simply therapeutical administration.

Original languageHungarian
Pages (from-to)2095-2101
Number of pages7
JournalOrvosi Hetilap
Volume146
Issue number41
Publication statusPublished - 2005

Fingerprint

Anticoagulants
Stroke
Therapeutics
Warfarin
Pharmaceutical Preparations
Multicenter Studies
Guidelines
Antithrombins
Platelet Aggregation Inhibitors
Platelet Aggregation
Atrial Fibrillation
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A thrombocytaaggregáció-gátló és az antikoaguláns kezelés aktuális szempontjai a stroke prevenciójában. / Szapáry, L.

In: Orvosi Hetilap, Vol. 146, No. 41, 2005, p. 2095-2101.

Research output: Contribution to journalArticle

@article{1f71fafedb8d46369dda80328cd3cbdb,
title = "A thrombocytaaggreg{\'a}ci{\'o}-g{\'a}tl{\'o} {\'e}s az antikoagul{\'a}ns kezel{\'e}s aktu{\'a}lis szempontjai a stroke prevenci{\'o}j{\'a}ban",
abstract = "About 80{\%} of strokes have ischemic origin. Therapeutical options of acute stroke are still limited and the occurrence of recurrent strokes is remarkably high. Consequently, the adequate stroke prevention has a high importance. The two main components of prevention are the inhibition of platelet aggregation and the anticoagulant therapy. Results of multicenter drug trials showed that antiaggregation therapy can reduce the risk of recurrent stroke by ca. 25{\%}. Acetylsalicylate has been used for stroke prevention for decades. Nowadays, there is a broad spectrum of available platelet aggregation inhibitors. The efficacy of these new drugs is higher than that of acetylsalicylate. According to recent therapeutical guidelines, the antiaggregation therapy of patients with non-cardiometabolic stroke should be optimized individually. The most frequent cause of cardiogenic stroke is atrial fibrillation. The importance of anticoagulation therapy has been proved by large multicenter studies. Absolute therapeutical indications are the elder age, additional risk factors, previous stroke. Therapeutical guidelines in other cardiological disorders associated with high risks for stroke need further drug trials. Fifty years after the introduction of warfarin, in the last years new direct thrombin inhibitors have been developed. These drugs have the same efficacy as warfarin but they are a more safety and have more simply therapeutical administration.",
keywords = "Anticoagulation, Antiplatelet treatment, Ischemic stroke",
author = "L. Szap{\'a}ry",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "2095--2101",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "41",

}

TY - JOUR

T1 - A thrombocytaaggregáció-gátló és az antikoaguláns kezelés aktuális szempontjai a stroke prevenciójában

AU - Szapáry, L.

PY - 2005

Y1 - 2005

N2 - About 80% of strokes have ischemic origin. Therapeutical options of acute stroke are still limited and the occurrence of recurrent strokes is remarkably high. Consequently, the adequate stroke prevention has a high importance. The two main components of prevention are the inhibition of platelet aggregation and the anticoagulant therapy. Results of multicenter drug trials showed that antiaggregation therapy can reduce the risk of recurrent stroke by ca. 25%. Acetylsalicylate has been used for stroke prevention for decades. Nowadays, there is a broad spectrum of available platelet aggregation inhibitors. The efficacy of these new drugs is higher than that of acetylsalicylate. According to recent therapeutical guidelines, the antiaggregation therapy of patients with non-cardiometabolic stroke should be optimized individually. The most frequent cause of cardiogenic stroke is atrial fibrillation. The importance of anticoagulation therapy has been proved by large multicenter studies. Absolute therapeutical indications are the elder age, additional risk factors, previous stroke. Therapeutical guidelines in other cardiological disorders associated with high risks for stroke need further drug trials. Fifty years after the introduction of warfarin, in the last years new direct thrombin inhibitors have been developed. These drugs have the same efficacy as warfarin but they are a more safety and have more simply therapeutical administration.

AB - About 80% of strokes have ischemic origin. Therapeutical options of acute stroke are still limited and the occurrence of recurrent strokes is remarkably high. Consequently, the adequate stroke prevention has a high importance. The two main components of prevention are the inhibition of platelet aggregation and the anticoagulant therapy. Results of multicenter drug trials showed that antiaggregation therapy can reduce the risk of recurrent stroke by ca. 25%. Acetylsalicylate has been used for stroke prevention for decades. Nowadays, there is a broad spectrum of available platelet aggregation inhibitors. The efficacy of these new drugs is higher than that of acetylsalicylate. According to recent therapeutical guidelines, the antiaggregation therapy of patients with non-cardiometabolic stroke should be optimized individually. The most frequent cause of cardiogenic stroke is atrial fibrillation. The importance of anticoagulation therapy has been proved by large multicenter studies. Absolute therapeutical indications are the elder age, additional risk factors, previous stroke. Therapeutical guidelines in other cardiological disorders associated with high risks for stroke need further drug trials. Fifty years after the introduction of warfarin, in the last years new direct thrombin inhibitors have been developed. These drugs have the same efficacy as warfarin but they are a more safety and have more simply therapeutical administration.

KW - Anticoagulation

KW - Antiplatelet treatment

KW - Ischemic stroke

UR - http://www.scopus.com/inward/record.url?scp=33644829642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644829642&partnerID=8YFLogxK

M3 - Article

C2 - 16304802

AN - SCOPUS:33644829642

VL - 146

SP - 2095

EP - 2101

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 41

ER -